Abstract: The present invention related to a universal semiconductor switch. In one embodiment, the switch includes a switching arrangement having an input power connection configured as input for a solid state switching device, the solid state switching device operationally coupled to a current limiting arrangement and an output circuit; the output circuit including a filter circuit. At least one trigger circuit including a power source and an on-and-off circuit, said trigger circuit operably coupled to the switching arrangement input power source and the solid state switching device. An on-command noise immunity circuit and an off-command noise immunity circuit are operationally coupled to the trigger circuit to suppress the noise from any external source, the switch will trigger only if the detected voltage is beyond the threshold voltage and for a predetermined duration.

Abstract: A method and system are disclosed for capturing observations of customer-premise equipment or customer-provided equipment (CPE) devices. The method includes reporting a problem detect by a user during use of a customer-premise equipment or customer-provided equipment (CPE) device with one or more specific buttons on a remote controller; and entering the problem into a log with a timestamp.

Abstract: The present invention relates to a process for preparing the Alectinib or a pharmaceutically acceptable salt thereof using lesser reaction steps and also eliminating expensive and time-consuming column chromatography. The invention also relates to novel polymorphic forms of Alectinib and Alectinib hydrochloride.

Abstract: A method comprising receiving a first set of aerial images of a geographic area, receiving locations of assets, determining a likely location of at least one asset within each image, creating one or more bounding boxes, encompassing the likely location of one or more assets within each of the images, providing any number of the images to a convolutional neural network to classify pixels, the classification of each of the pixels indicating if the pixels are part of one or more obstructions or are part of a different classification, determining at least one zone, the zone encompassing the at least one asset, determining a distance between at least one pixel part of an obstruction and the zone, generating a criticality score based on the distance, comparing the criticality score to a threshold, and providing an alert of a future hazardous condition based on the criticality score.

Abstract: The present invention relates to a process for preparing the Alectinib or a pharmaceutically acceptable salt thereof using lesser reaction steps and also eliminating expensive and time-consuming column chromatography. The invention also relates to novel polymorphic forms of Alectinib and Alectinib hydrochloride.

Abstract: The present invention relates to an improved process for the synthesis of bendamustine, in particular, bendamustine hydrochloride of the formula (VI) and its intermediate 1-methyl-5-[bis(2-chloroethyl)amino]-1H-benzimidazol-2-yl]lithium butanoate of formula (V), both having a purity of ?99%, which is simple, convenient, economical, does not use hazardous chemicals and is industrially viable.

Abstract: A system and method for displaying a first intruder aircraft symbology on a lateral map display and on a vertical situation display is provided. Symbology is generated that is graphically representative of the first intruder aircraft on the lateral map display and the VSD. Additional symbology is generated to correlate the first intruder aircraft on the lateral map display to that on the vertical situation display.

Abstract: The present invention provides process for preparation of crystalline Bortezomib (Ia) as its monohydrate which is designated as crystalline Form-SB and characterized by having water content ranging between 3.5-6.0% w/w; X-ray powder diffraction pattern comprising characteristic 20° peaks selected from the XRPD peak set of 5.6, 7.5, 9.8, 10.2, 11.3, 15.1, 18.0, 20.5, 21.5 and 23.6±0.20 2?°, wherein peaks at 9.8 and 11.39±0.20 2?° are un-split and 100% intensity peak is present at 5.6±0.20 2?°, DSC isotherm comprising the endothermic peaks ranging between 45 to 60° C. (Peak-1) and 175 to 185° C. (Peak-2) and IR absorption characteristic peaks approximately at 3387 cm?1, 3304 cm?1, 2953 cm?1, 2927 cm?1, 2868 cm?1, 1627 cm?1, 1455 cm?1, 1400 cm?1, 1201 cm?1, 1150 cm?1, 1020 cm?1, 747 cm?1 and 702 cm?1 and Raman absorption spectra having characteristic peaks approximately at 3066 cm?1, 1583 cm?1, 1528 cm?1, 1281 cm?1, 1213 cm?1, 1035 cm?1, 1022 cm?1 and 1004 cm?1.

Abstract: The present invention relates to an improved process for the synthesis of bendamustine, in particular, bendamustine hydrochloride of the formula (VI) and its intermediate 1-methyl-5-[bis(2-chloroethyl)amino]-1H-benzimidazol-2-yl]lithium butanoate of formula (V), both having a purity of ?99%, which is simple, convenient, economical, does not use hazardous chemicals and is industrially viable.

Abstract: The present invention relates to an improved process for the synthesis of bendamustine, in particular, bendamustine hydrochloride of the formula (VI) and its intermediate 1-methyl-5-[bis(2-chloroethyl)amino]-1H-benzimidazol-2-yl]lithium butanoate of formula (V), both having a purity of ?99%, which is simple, convenient, economical, does not use hazardous chemicals and is industrially viable.

Abstract: A system and method for displaying a first intruder aircraft symbology on a lateral map display and on a vertical situation display is provided. Symbology is generated that is graphically representative of the first intruder aircraft on the lateral map display and the VSD. Additional symbology is generated to correlate the first intruder aircraft on the lateral map display to that on the vertical situation display.

Abstract: The present invention relates to novel heterocyclic diphenyl ether and diphenyl amine compounds, derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and pharmaceutically acceptable solvates thereof and pharmaceutically acceptable compositions containing these singly or in combination. The compounds of the present invention are effective in lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels and are useful in the treatment and/or prophylaxis of diabetes. The compounds of the present invention are effective in treatment of obesity, inflammation, autoimmune diseases such as multiple sclerosis and rheumatoid arthritis and immunological diseases, including the treatment of cancer. Furthermore, the compounds are useful for the treatment of disorders associated with insulin resistance.

Abstract: This invention relates to heteroaryl substituted fused bicyclic heteroaryl compounds, such as heteroaryl substituted imidazopyridines, imidazopyrazines, imidazopyridizines, imidazopyrimidines, and imidazothiazoles, which may be described by Formula I or Formula II: The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Processes for preparing compounds of Formula I and Formula II are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I or Formula II in combination with one or more other CNS agents to potentiate the effects of the other CNS agents.

Abstract: This invention relates to heteroaryl substituted fused bicyclic heteroaryl compounds, such as heteroaryl substituted imidazopyridines, imidazopyrazines, imidazopyridizines, imidazopyrimidines, and imidazothiazoles, which may be described by Formula I or Formula II: The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Processes for preparing compounds of Formula I and Formula II are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I or Formula II in combination with one or more other CNS agents to potentiate the effects of the other CNS agents.

Abstract: This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAA receptors in tissue sections.

Abstract: The present invention is related to compounds having general formula Z-OC (CRn1Rn2)—CO-Z wherein Z=OH or NH2 and n1=n2=1 to 8, useful for modulation of immune response by inducing differentiation of dendritic cells consisting novel class of amino acid derivatives (sulfonic acid/sulfate derivatives of naturally occurring amino acids, and their amides) of the general formula ZOC—CR3R4—CR2(NHR1)—COOH, ZOC—CR5R6—CR3R4—CR1(NHR2)—COOH, ZOC—CR7R8—CR5R6—CR3R4—CR1N2)—COOH wherein Z=OH or NH2; R1 to R8 denotes H, SO3H, or OSO3H. In addition, the dicarboxylic acids and their amides ZOC—(CH2)n—CR1R2—COOH, where Z=OH or NH2; and n=1, 2, 3. The groups R1/R2=H/SO3H or OSO3H or CH2—SO3H or CH2—OSO3H and vice versa. The factors also contain different divalent metal cations such as Mg, Ca and Zn.

Abstract: The present invention is related to compounds having general formula Z-OC(CRn1Rn2)—CO-Z wherein Z=OH or NH2 and n1=n2=1 to 8, for modulation of immune response by differentiation dendritic cells consisting novel class of amino acid derivatives (sulfonic acid/sulfate derivatives of naturally occurring amino acids, and their amides) of the general formula ZOC—CR3R4—CR2(NHR1)—COOH, ZOC—CR5R6—CR3R4—C(NHR2)—COOH, ZOC—CR7R8—CR5R6—CR3R4—CR1(NHR2)—COOH wherein Z=OH or NH2; R1 to R8 denotes H, SO3H, or OSO3H. In addition, the dicarboxylic acids and their amides ZOC—(CH2)n—CR1R2—COOH, where Z=OH or NH2; and n=1, 2, 3. The groups R1/R2=H/SO3H or OSO3H or CH2—SO3H or CH2—OSO3H and vice versa. The factors also contain different divalent metal cations such as Mg, Ca and Zn.

Abstract: This invention relates to a novel class of acidic amino acid/dicarboxylic acid derivatives (sulfonic acid/sulfate derivatives of naturally occurring amino acids and their amides) useful as inhibitors of osteoclastogenesis. The invention also provides methods of using the novel class of acidic amino acid/dicarboxylic acid derivatives of the general formula ZOC—(CRR)m—COOH, wherein: m=2, 3 or 4; Z is OH or NH2; one R in the compound is from the group consisting of SO3H, OSO3H, CH2—SO3H, CH2—OSO3H, and NHSO3H, and the remaining Rs are H or NH2, for inhibition of osteoclastogenesis.

Abstract: This invention relates to heteroaryl substituted fused bicyclic heteroaryl compounds, such as heteroaryl substituted imidazopyridines, imidazopyrazines, imidazopyridizines, imidazopyrimidines, and imidazothiazoles, which may be described by Formula I or Formula II: 1

Abstract: This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I 1